

Radiotherapy (Adults) Quality Dashboard 2020/21



Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes (General)	Reporting Periods			
															Q1	Q2	Q3	Q4
RAD12a		Waiting times	Outcome measure		Number of patients waiting longer than 31 days from decision to treat date to date of first treatment - radical	Of those in the denominator, the number of patients who waited longer than 31 days from decision to treat date to date of first treatment date	The total number of radical patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Include all cancers. Non cancers excluded	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD12b		Waiting times	Outcome measure		Number of patients waiting longer than 31 days from decision to treat date to date of first treatment - palliative	Of those in the denominator, the number of patients who waited longer than 31 days from decision to treat date to date of first treatment date	The total number of palliative patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Include all cancers. Non cancers excluded	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD13a		Activity	Outcome measure		Number of episodes of radical treatment by tumour site - lung, including SABR (Stereotactic Ablative Body Radiotherapy)	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (lung only, INCLUDING SABR)	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD13b		Activity	Outcome measure		Number of episodes of radical treatment by tumour site - lung SABR (Stereotactic Ablative Body Radiotherapy) only	Of those in the denominator, the number of episodes where treatment was SABR	The total number of radical treatment episodes in the reporting period (lung only)	Annual	Annual	PHE	PHE		Higher is better	Data pulled using OPCS code Y91.5	N/A	N/A	N/A	Apr 19 - Mar 20
RAD13c		Activity	Outcome measure		Number of episodes of radical treatment by tumour site - head and neck only	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (head and neck only)	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD13d		Activity	Outcome measure		Number of episodes of radical treatment by tumour site - cervix	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (cervix only)	Annual	Annual	PHE	PHE		Higher is better	Data pulled using ICD 10 code C53	N/A	N/A	N/A	Apr 19 - Mar 20
RAD14		IMRT	Process measure		Proportion of all Radiotherapy Radical episodes receiving Inverse Planned IMRT (excluding breast)	Of those in the denominator, the number of episodes where the patient received Inverse Planned IMRT	The total number of new treatment episodes where intent was radical in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Use delivery OPCS X671. Exclude breast cancer, brachytherapy and non melanoma (C44) in the numerator and brachytherapy and non melanoma in the denominator.	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD15a		Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical lung patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of lung episodes in the reporting period	Annual	Annual	PHE	PHE	50%	Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD15b		Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical prostate patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of prostate episodes in the reporting period	Annual	Annual	PHE	PHE	50%	Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD15c		Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical head and neck patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of head and neck episodes in the reporting period	Annual	Annual	PHE	PHE	100%	Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD16		Waiting times	Outcome measure	Mean number of days	Mean waiting time (in days) from date of referral to radiotherapy department to the date of treatment commencing for Category 1 patients	Of those in the denominator, the total number of days waited from date of referral to RT dept to date of treatment commencing	The total number of patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Category 1 patients - Squamous cell carcinoma head and neck, cervix, vagina and vulva, anus,, all radical lung, all radical oesophagus	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD17		Breast cancer radiotherapy	Outcome measure		Proportion of patients for whom radiotherapy is indicated as part of treatment for breast cancer less than or equal to 15 fractions (excluding any boost)	Of those in the denominator, the number where the radiotherapy is less than or equal to 15 fractions	The total number of breast cancer patients receiving radiotherapy in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Teletherapy only. Excludes electrons	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD18		Metastatic bone radiotherapy	Outcome measure		Proportion of metastatic bone radiotherapy episodes treated with a single fraction of external beam radiotherapy	Of those in the denominator, the number where external beam radiotherapy treated with a single fraction	The total number of metastatic bone radiotherapy episodes in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Excludes spinal cord compression	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD19		Prostate cancer radiotherapy	Outcome measure		Proportion of prostate cancer patients treated with radical external beam radiotherapy using 5, 19 or 20 fractions of treatment	Of those in the denominator, the number where external beam radiotherapy is 5, 19 or 20 fractions	The total number of prostate cancer patients receiving radical radiotherapy (5, 19 20 or more) in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Teletherapy only include all patients	Jan 20 - Mar 20	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20
RAD20		Fractions per linac	Process measure		Departmental average number of fractions per linac	The total number of fractions	The total number of linacs	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20

Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes (General)	Reporting Periods			
															Q1	Q2	Q3	Q4
RAD21		Trials	Process measure		Proportion of patients recruited to trials	Of those in the denominator, the number who are recruited to a trial	The total number of patients receiving treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better		N/A	N/A	N/A	Apr 19 - Mar 20
RAD22		Mortality	Outcome measure		30 day mortality rate (adult palliative patients only excluding MSCC)	TBC	TBC	TBC	TBC	PHE	PHE		Lower is better	Data not currently available To be developed				
RAD23		Mortality	Outcome measure		90 day mortality rate (post radical radiotherapy adults only)	TBC	TBC	TBC	TBC	PHE	PHE		Lower is better	Data not currently available To be developed				
Data collection has been approved by the Review of Central Returns - ROCR ROCR/OR/2230/001MAND																		